<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36429">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632292</url>
  </required_header>
  <id_info>
    <org_study_id>15-260</org_study_id>
    <nct_id>NCT02632292</nct_id>
  </id_info>
  <brief_title>EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus</brief_title>
  <acronym>SUGAR-EVE</acronym>
  <official_title>EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Schleswig-Holstein, Campus Kiel, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kerckhoff Klinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, controlled, multicenter, open-label study to compare
      everolimus-eluting bioresorbable vascular scaffolds to everolimus-eluting stents in patients
      with diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late lumen loss</measure>
    <time_frame>Angiography 8-10 months after the index procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Baseline angiography</time_frame>
    <description>Attainment of &lt;30% final residual stenosis following the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>Baseline angiography</time_frame>
    <description>Device success and no periprocedural complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasomotion</measure>
    <time_frame>Angiography 8-10 months after the index procedure</time_frame>
    <description>Change in minimal lumen diameter before and after nitrate administration assessed by angiography at 8-10 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment late lumen loss</measure>
    <time_frame>Angiography 8-10 months after the index procedure</time_frame>
    <description>Difference between the immediate post-procedure in-stent minimal lumen diameter and the in-stent minimal lumen diameter assessed by angiography at 8-10 months inside the stent or within 5 mm proximal or distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis</measure>
    <time_frame>Angiography 8-10 months after the index procedure</time_frame>
    <description>In-stent or in-segment restenosis ≥50% assessed by angiography at 8-10 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conformability</measure>
    <time_frame>Angiography 8-10 months after the index procedure</time_frame>
    <description>Change in curvature and angulation between preprocedure, postprocedure, and angiographic follow-up at 8-10 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>12- and 24-months</time_frame>
    <description>Composite of cardiac death, myocardial infarction, scaffold/stent thrombosis, and target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12- and 24-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12- and 24-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scaffold/stent thrombosis</measure>
    <time_frame>12- and 24-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12- and 24-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>12- and 24-months</time_frame>
    <description>Composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>12- and 24-months</time_frame>
    <description>Composite of cardiac death, target vessel related myocardial infarction, clinically driven target vessel revascularization, and scaffold/stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>12- and 24-months</time_frame>
    <description>Procedure success and no major adverse cardiac events at 12- and 24-month clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anginal status assessed by the Seattle Angina Questionnaire</measure>
    <time_frame>12- and 24-months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Absorb GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioresorbable everolimus-eluting scaffolds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Promus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus-eluting stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorb GT1</intervention_name>
    <description>Bioresorbable vascular scaffold</description>
    <arm_group_label>Absorb GT1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Promus</intervention_name>
    <description>Everolimus-eluting stent</description>
    <arm_group_label>Promus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical inclusion criteria:

          -  Age ≥18 years

          -  DM type I or II based on the definitions of the American Diabetes Association

          -  Angiographically proven CAD

          -  Angina pectoris, equivalent symptoms, and/or positive stress test, and/or
             instantaneous flow reserve ≤0.86, and/or fractional flow reserve ≤0.80

          -  Negative pregnancy test in women with childbearing potential

        Angiographic inclusion criteria:

          -  De-novo lesion in at least one native coronary artery

          -  Luminal diameter reduction 50-99% assessed by visual estimation

          -  Target reference vessel diameter 2.5 - 4.0 mm

        Clinical exclusion criteria:

          -  Limited long-term prognosis with a life-expectancy &lt;12 months

          -  Contraindications to antiplatelet therapy

          -  Known allergy against cobalt chrome, everolimus, or polylactic acid

        Angiographic exclusion criteria:

          -  Target lesion located in the left main trunk

          -  Severe calcification of the target lesion as determined by angiography

          -  In-stent restenosis

          -  Bifurcation lesion with planned two-stent strategy

          -  Chronic total occlusion

          -  Indication for CABG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suzanne de Waha, MD</last_name>
    <phone>+49451500</phone>
    <phone_ext>2501</phone_ext>
    <email>suzanne.dewaha@uksh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele</last_name>
      <email>holger.thiele@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Roza Meyer-Saraei</last_name>
      <email>roza.meyer-saraei@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Holger Thiele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>December 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Holger Thiele</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
